Table 2.
Study site | Number of isolates | Resistance pattern |
MIC (μg/ml) |
Integrons |
DNA Gyrase A mutation |
Replicon plasmid | |||
---|---|---|---|---|---|---|---|---|---|
AZM | NA | CIP | Ser83 | Asp87 | |||||
Bhutan |
19 |
S, SXT, TE, NA, CIP |
3.0-4.0 |
>256 |
3.0-4.0 |
Class 2 |
Ser83Leu |
Asp87Gly |
ColE |
Bhutan |
9 |
S, SXT, TE, NA, CIP |
3.0-4.0 |
>256 |
3.0-4.0 |
Class 2 |
Ser83Leu |
Asp87Gly |
B/O, ColE |
Bhutan |
1 |
S, SXT, TE, NA, CIP |
4.0 |
>256 |
3.0 |
Class 2 |
Ser83Leu |
Asp87Gly |
I1, ColE |
Nepal |
1 |
S, SXT, TE, NA, CIP |
4.0 |
>256 |
4.0 |
Class 2 |
Ser83Leu |
Asp87Gly |
ColE |
Nepal |
2 |
S, SXT, TE, NA |
3.0-4.0 |
>256 |
0.190-0.125 |
Class 2 |
Ser83Leu |
Neg |
ColE |
Nepal |
1 |
S |
3.0 |
3.0 |
0.008 |
Neg |
Neg |
Neg |
ColE |
Thailand |
1 |
S, SXT, TE, NA, AM |
3.0 |
>256 |
0.190 |
Neg |
Ser83Leu |
Neg |
B/O, ColE |
Thailand |
1 |
S, SXT, TE, AM |
3.0 |
3.0 |
0.004 |
Neg |
Neg |
Neg |
I1, ColE |
Thailand |
2 |
S, SXT, TE, NA, AM |
3.0-4.0 |
128 |
0.004 |
Class 2 |
Neg |
Asp87Tyr |
I1, ColE |
Thailand | 1 | S, SXT, TE, NA, | 4.0 | >256 | 0.004 | Class 2 | Ser83Leu | Neg | ColE |
AZM, azithromycin; NA, nalidixic acid; CIP, ciprofloxacin; AM, ampicillin; SXT, trimethoprim-sulfamethoxazole; CRO, ceftriaxone; S, streptomycin; TE, tetracycline; Ser, Serine; Leu, Leucine; Asp, Aspartic acid; Gly, Glycine; Tyr, Tyrosine; Neg, negative result.